Page 3 - ஆம்ஸ்டர்டாம் பல்கலைக்கழகம் மருத்துவ மையங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EyeYon Medical Receives CE Mark for its EndoArt® Implant to Treat Chronic Corneal Edema Font : A-A+ EndoArt® previously received Innovative Device Status by the Chinese NMPA, and Breakthrough Device Designation from the US Food and Drug Administration TEL AVIV, Israel, June 8, 2021 /PRNewswire/  EyeYon Medical, an Israeli start-up company developing a variety of ophthalmic products for vision-threatening conditions, announced today that it has received CE Mark for its EndoArt®, after clinical trials demonstrated safety and efficacy for treating chronic corneal edema. The CE Mark serves as approval by the European Union (EU) to commercialize EndoArt®, the world s first and only synthetic implant, which replaces the human endothelium that the human body can never regenerate. The current standard of care involves corneal transplantation of human tissue. This unique implant enables doctors to treat endothelial-related chronic corneal edema with a minimally invasive surger

Comunidad autonoma de catalunaNoord hollandNahum fereraAmsterdam university medical centersEuropean unionDrug administrationEyeyon medicalInnovative device statusBreakthrough device designationInstituto de microcirugia ocularRuth lapid gortzakPrincipal investigatorOfer daphnaYon medicalArtificial endothelial layerBinyamin tjong alvaresrimon cohen